Clinical management of achalasia: current state of the art

被引:24
作者
Krill, Joseph T. [1 ]
Naik, Rishi D. [1 ]
Vaezi, Michael F. [1 ]
机构
[1] Vanderbilt Univ, Med Ctr, Ctr Swallowing & Esophageal Disorders, Div Gastroenterol Hepatol & Nutr, Nashville, TN USA
来源
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY | 2016年 / 9卷
关键词
achalasia; pseudoachalasia; pneumatic dilation; Heller myotomy; botulinum toxin injection; peroral endoscopic myotomy;
D O I
10.2147/CEG.S84019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Achalasia is a primary disorder of esophageal motility. It classically presents with dysphagia to both solids and liquids but may be accompanied by regurgitation and chest pain. The gold standard for the diagnosis of achalasia is esophageal motility testing with manometry, which often reveals aperistalsis of the esophageal body and incomplete lower esophageal sphincter relaxation. The diagnosis is aided by complimentary tests, such as esophagogastroduodenoscopy and contrast radiography. Esophagogastroduodenoscopy is indicated to rule out mimickers of the disease known as "pseudoachalasia" (eg, malignancy). Endoscopic appearance of a dilated esophagus with retained food or saliva and a puckered lower esophageal sphincter should raise suspicion for achalasia. Additionally, barium esophagography may reveal a dilated esophagus with a distal tapering giving it a "bird's beak" appearance. Multiple therapeutic modalities aid in the management of achalasia, the decision of which depends on operative risk factors. Conventional treatments include medical therapy, botulinum toxin injection, pneumatic dilation, and Heller myotomy. The last two are defined as the most definitive treatment options. New emerging therapies include peroral endoscopic myotomy, placement of self-expanding metallic stents, and endoscopic sclerotherapy.
引用
收藏
页码:71 / 82
页数:12
相关论文
共 101 条
[1]  
Ali A, 2001, Gastrointest Endosc Clin N Am, V11, P347
[2]  
Ali A, 2001, GASTROINTEST ENDOSC, V11, pvii
[3]  
Ali A, 2001, GASTROINTEST ENDOSC, V11, p[vii, 274]
[4]   Evaluation of the response to treatment in patients with idiopathic achalasia by the timed barium esophagogram: results from a randomized clinical trial [J].
Andersson, M. ;
Lundell, L. ;
Kostic, S. ;
Ruth, M. ;
Lonroth, H. ;
Kjellin, A. ;
Hellstrom, M. .
DISEASES OF THE ESOPHAGUS, 2009, 22 (03) :264-273
[5]   A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia [J].
Annese, V ;
Bassotti, G ;
Coccia, G ;
Dinelli, M ;
D'Onofrio, V ;
Gatto, G ;
Leandro, G ;
Repici, A ;
Testoni, PA ;
Andriulli, A .
GUT, 2000, 46 (05) :597-600
[6]   The Pathogenesis and Management of Achalasia: Current Status and Future Directions [J].
Ates, Fehmi ;
Vaezi, Michael F. .
GUT AND LIVER, 2015, 9 (04) :449-463
[7]   Peroral endoscopic myotomy: an evolving treatment for achalasia [J].
Bechara, Robert ;
Ikeda, Haruo ;
Inoue, Haruhiro .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2015, 12 (07) :410-426
[8]   A Comparative Study on Comprehensive, Objective Outcomes of Laparoscopic Heller Myotomy With Per-Oral Endoscopic Myotomy (POEM) for Achalasia [J].
Bhayani, Neil H. ;
Kurian, Ashwin A. ;
Dunst, Christy M. ;
Sharata, Ahmed M. ;
Rieder, Erwin ;
Swanstrom, Lee L. .
ANNALS OF SURGERY, 2014, 259 (06) :1098-1103
[9]   VISCEROTOPIC REPRESENTATION OF THE UPPER ALIMENTARY-TRACT IN THE MEDULLA-OBLONGATA IN THE RAT - THE NUCLEUS AMBIGUUS [J].
BIEGER, D ;
HOPKINS, DA .
JOURNAL OF COMPARATIVE NEUROLOGY, 1987, 262 (04) :546-562
[10]  
Boeckxstaens Guy, 2011, Gastroenterol Hepatol (N Y), V7, P609